Protect Animal Health and Rejuvenate Bio have announced a partnership to develop cell therapies targeting degenerative mitral valve disease (DMVD) in dogs, which the companies say is a leading cause of death among older small breeds.
The companies said the collaboration will combine Protect’s veterinary market expertise with Rejuvenate Bio’s proprietary gene and cell therapy platforms. According to Rejuvenate Bio, its technology has shown potential to treat age-related conditions, including DMVD, by reprogramming cellular pathways associated with aging.
The agreement includes plans to co-develop therapies and pursue regulatory approvals in key markets. Protect Animal Health will lead product registration and commercial distribution, while Rejuvenate Bio will focus on research and development. The company claims its approach could slow disease progression and improve heart function in affected dogs.
The companies said that DMVD accounts for more than 75% of canine heart disease cases in the United States and Europe, affecting millions of pets annually. By targeting the underlying biological mechanisms, the partnership aims to provide a new therapeutic option for veterinarians and pet owners.
According to the announcement, initial preclinical studies are expected to begin within the next year, with clinical trials planned to follow. Both companies see potential for broader applications of the technology to other age-related diseases in companion animals.
